Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials
Omar S. Alkhezi, Abdullah A. Alahmed, Osamah M. Alfayez, et al.
Obesity Reviews (2022) Vol. 24, Iss. 3
Closed Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Obesity Management in Adults
Arielle Elmaleh-Sachs, Jessica L. Schwartz, Carolyn T. Bramante, et al.
JAMA (2023) Vol. 330, Iss. 20, pp. 2000-2000
Open Access | Times Cited: 215
Vegetarian and vegan diets: benefits and drawbacks
Tian Wang, Andrius Masedunskas, Walter C. Willett, et al.
European Heart Journal (2023) Vol. 44, Iss. 36, pp. 3423-3439
Open Access | Times Cited: 75
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, et al.
Annals of Internal Medicine (2025) Vol. 178, Iss. 2, pp. 199-217
Closed Access | Times Cited: 5
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 34
Advances in the management of type 2 diabetes in adults
Rodolfo J. Galindo, Jennifer M. Trujillo, Cecilia C. Low Wang, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000372-e000372
Open Access | Times Cited: 30
Weight loss efficiency and safety of tirzepatide: A Systematic review
Fei Lin, Bin Yu, Baodong Ling, et al.
PLoS ONE (2023) Vol. 18, Iss. 5, pp. e0285197-e0285197
Open Access | Times Cited: 29
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, et al.
Metabolism (2023) Vol. 149, pp. 155710-155710
Closed Access | Times Cited: 27
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study
Hannah Moll, E.A. Frey, Philipp A. Gerber, et al.
EClinicalMedicine (2024) Vol. 73, pp. 102661-102661
Open Access | Times Cited: 14
Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials
Gustavo de Oliveira Almeida, Thiago Nienkötter, Caroline Cristine Almeida Balieiro, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 4, pp. 509-521
Closed Access | Times Cited: 9
Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center
Karen Muschler, Rachael Muschalek, Christopher Hoyte
Clinical Toxicology (2025), pp. 1-4
Closed Access | Times Cited: 1
Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review
P Schmidt, Eric Pasqualotto, Henrique Vilar dos Santos, et al.
Obesity Research & Clinical Practice (2025)
Closed Access | Times Cited: 1
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial
Emily R. Hankosky, Hui Wang, Lisa M. Neff, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 12, pp. 3748-3756
Open Access | Times Cited: 19
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
Özge Telci Çaklılı, Mustafa Cesur, Dimitri P. Mikhailidis, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 1767-1774
Open Access | Times Cited: 16
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 7
Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials
Ligang Liu, Hekai Shi, Merilyn Xie, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 6, pp. 1268-1280
Open Access | Times Cited: 6
Adjuvant and Neo-Adjuvant Anti-Obesity Medications and Bariatric Surgery: A Scoping Review
Theo Sher, Michelle Y. McGee, Christopher DuCoin, et al.
Current Obesity Reports (2024) Vol. 13, Iss. 2, pp. 377-402
Closed Access | Times Cited: 4
Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
Rodrigo B. Mansur, Joshua D. Di Vincenzo, Sebastian Badulescu, et al.
CNS Spectrums (2025), pp. 1-6
Closed Access
Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis
Zhige Wen, Wenjie Sun, Haoshuo Wang, et al.
Diabetes Research and Clinical Practice (2025), pp. 111999-111999
Closed Access
A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass
Ali Lahooti, Anna Carolina Hoff, Brian Critelli, et al.
Obesity Surgery (2025)
Closed Access
The Impact of Novel Medications for Obesity on Weight Stigma and Societal Attitudes: A Narrative Review
Berit L. Heitmann
Current Obesity Reports (2025) Vol. 14, Iss. 1
Open Access
Non-communicable diseases in Saudi adolescents: prevalence, risk factors, and implications for public health
Mansour Almuqbil, Syed Imam Rabbani, Rafiulla Gilkaramenthi, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access
Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis
Shaolong Zhang, Boran Yu, Jiamin Xu, et al.
Diabetes Technology & Therapeutics (2025)
Closed Access
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access
Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review
Jason Zupec, R Munger, Alice L. Scaletta, et al.
Nutrition in Clinical Practice (2025)
Closed Access
Page 1 - Next Page

Scroll to top